

WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[HA599 trade name]*

Sulfamethoxazole/trimethoprim 800 mg/160 mg tablets

[HA599 trade name], manufactured at Micro Labs Limited, Bangalore, Karnataka, India, was included in the WHO list of prequalified medicinal products for HIV/AIDS on 23 May 2016.

[HA599 trade name] is indicated for treatment/prevention of certain opportunistic infections in patients with HIV/AIDS. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredients of [HA599 trade name] are sulfamethoxazole and trimethoprim.

The efficacy and safety of sulfamethoxazole and trimethoprim are well established based on extensive clinical experience in HIV/AIDS management.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of sulfamethoxazole/trimethoprim in HIV/AIDS, the team of assessors advised that [HA599 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [HA599 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [HA599 trade name]:

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Initial acceptance	Date	Outcome
Status on PQ list	23 May 2016	Listed
Pharmaceutical quality	07 July 2016	MR
Bioequivalence	09 July 2016	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	05 February 2015	MR
FPP	10 December 2015	MR
GCP/GLP (re-)inspection	NA	NA
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification		

The table represents the status of relevant completed activities only.

Requalification	8 March 2023
------------------------	--------------